Chronic kidney disease: A perspective

Journal, Indian Academy of Clinical Medicine

Volumn 8, Issue 2, 2007, Pages 150-163

  Shyam, C ^a   Duggal, Ashish K ^a   Sunder, S ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE COURSE; HEALTH CARE; HEALTH CARE PLANNING; HUMAN; LIFE EXPECTANCY; MORBIDITY; MORTALITY; POPULATION; PREVALENCE; REVIEW;

EID: 34250716510     PISSN: 09723560     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol 2002; 13 (Suppl 1): S37-40.
2. Kher V. End-stage renal disease in developing countries. Kidney Int 2002; 62: 350-62.
3. Coresh J, Astor BC, Greene T et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41 (1): 1-12.
4. Kidney Disease Outcome Quality Initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kid Dis 2002; 39 (Suppl 2): S1-246.
5. Levey AS, Greene T, Schluchter MD et al. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4 (5): 1159-71.
6. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130 (6): 461-70.
7. Cochran M, St John A. A comparison between estimates of GFR using (99mTc) DTPA clearance and the approximation of Cockroft and Gault. Aust N Z J Med 1993; 23 (5): 494-7.
8. Dharnidharka VR, Kwon C, Stevens G. Serum Cystatin C is superior to serum creatinine as a marker of kidney function: meta-analyses. Am J Kid Dis 2002; 40: 221-6.
9. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21 (9): 1414-31.
10. USRDS Annual data report: atlas of end stage renal disease in the United States. Bethesda: National Institute of Health. National Institute of Diabetes and Digestive and Kidney Diseases; 2003. Am J Kid Dis 2003; 42 (suppl 5): S37-173.
11. De Vecchi AF, Dratwa M, Wiedemann ME. Healthcare systems and end-stage renal disease (ESRD) therapies - an international review: costs and reimbursement/funding of ESRD therapies. Nephrol Dial Transplant 1999; 14 (Suppl 6):31-41.
12. United States Renal Data System. Annual data report: incidence and prevalence of ESRD (2003). Am J Kid Dis 2003; 42 (Suppl 5): S37-173.
13. McDonald SP, Russ GR, Kerr PG, Collins JF. Australia and New Zealand Dialysis and Transplant Registry. ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis 2002; 40 (6): 1122-31.
14. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: The Aus Diab kidney study. J Am Soc Nephrol 2003; 14 (7 Suppl 2): S131-8.
15. Iseki K. The Okinawa screening program. J Am Soc Nephrol 2003; 14 (7 Suppl 2): S127-30.
16. Hillege HL, Janssen WM, Bak AA et al. Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249 (6): 519-26.
17. Brown WW, Peters RM, Ohmit SE et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2003; 42 (1): 22-35.
18. Agarwal SK, Dash SC, Irshad M et al. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005; 20 (8): 1638-42.
19. Jones CA, McQuillan GM, Kusek JW et al. Serum creatinine levels in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 1998; 32 (6): 992-9.
20. Hogg RJ, Furth S, Lemley KV et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics 2003; 111 (6 Pt 1): 1416-21.
21. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139 (2): 137-47.
22. Mani MK. Experience with a programme for prevention of chronic renal failure in India. Kidney Int Suppl 2005; 94: S75-8.
23. Idem. Epidemiology of ESRD: a worldwide perspective. In: El Nahas M, ed. Kidney diseases in the developing world and ethnic minorities. London: Taylor and Francis, 2005; 1-13.
24. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
25. Chen MLW, Hsu C-Y. Should the K/DOQI definition of chronic kidney disease be changed? Am J Kid Dis 2003; 42: 623-25.
26. Bergman S, Key BO, Kirk KA et al. Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease. Am J Kidney Dis 1996; 27 (3): 341-6.
27. Buck K, Feehally J. Diabetes and renal failure in Indo-Asians in the UK - a paradigm for the study of disease susceptibility. Nephrol Dial Transplant 1997; 12 (8): 1555-7.
28. Brenner BM, Chertow GM. Congenital oligonephropathy and the aetiology of adult hypertension and progressive renal injury. Am J Kidney Dis 1994; 23 (2): 171-5.
29. Perry HM Jr, Miller JP, Fornoff JR et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 587-94.
30. Chobanian AV, Bakris GL, Black HR et al. Joint National Committee Prevention, Detection, and treatment of high Blood Pressure. National Heart, Lung, and Blood institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
31. Matts JP, Karnegis JN, Campos CT et al. Serum creatinine as an independent predictor of coronary heart disease mortality in normotensive survivors of myocardial infarction. POSCH Group. J Fam Pract 1993; 36: 497-503.
32. Anderson RJ, O'Brien M, Ma Whinney S et al. Renal failure predisposes patients to adverse outcomes after coronary artery bypass surgery. VA Cooperative Study #5. Kidney Int 1999; 55: 1057-62.
33. Rubenstein MH, Harell LC, Sheynberg BV et al. Are the patients with renal failure good candidates for percutaneous coronary revascularisation in the new device era? Circulation 2000; 102: 2966-72.
34. Szcech LA, Reddan DN, Owen WF et al. Differential survival after coronary revascularisation procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292-9.
35. McCullough PA, Soman SS, Shah SS et al. Risks associated with renal insufficiency in patients in coronary care unit. J Am Coll Cardiol 2000; 36: 697-84.
36. Shilpak MC, Fried Lf, Crump C et al. Cardiovascular disease risks tatus in elderly persons with renal insufficiency. Kidney Int 2002; 62: 997-1004.
37. Kasiske BL. Relationship between vascular disease and age associated changes in the human kidney. Kidney Int 1987; 31: 1153-9.
38. Culleton BF, Larson MG, Evans J et al. Prevalence and correlates of elevated serum creatinine levels. Arch Intern Med 1999; 159: 1785-90.
39. Curtis BM, Levin A, Parfrey PS. Multiple risk factor intervention in chronic kidney disease: management of Cardiac disease in chronic kidney disease patients. Med Clin N Am 2005; 89: 511-23.
40. El Nahas AM, Bello AK. Chronic kidney disease: the global challenge. Lancet 2005; 365: 331-40.
41. WHO. World Health Report 2003: Shaping the future. Geneva: WHO, 2003.
42. Jungers P, Chauveau P, Descamps-Latscha B et al. Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study. Nephrol Dial Transplant 1996; 11 (8): 1542-6.
43. Hannedouche T, Chauveau P, Kalou F et al. Factors affecting progression in advanced chronic renal failure. Clin Nephrol 1993; 39 (6): 312-20.
44. Hsu CY, Lin F, Vittinghoff E, Shlipak MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States. J Am Soc Nephrol 2003; 14 (11): 2902-7.
45. Jafar TH, Stark PC, Schmid CH et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139 (4): 244-52.
46. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63 (4): 1468-74.
47. Remuzzi G, Bertani T. N Engl J Med 1998; 339 (20): 1448-56.
48. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 1995; 47 (6): 1703-20.
49. Adler AI, Stevens RJ, Manley SE et al. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63 (1): 225-32.
50. Adler AI, Stevens RJ, Manley SE et al. UKPDS GROUP. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63 (1): 225-32.
51. Moorhead JF, Chan MK, El-Nahas M et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 1982; 2: 1309-11.
52. Johnson RJ, Kivlighn SD, Kim YG et al. Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999; 33 (2): 225-34.
53. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59 (4): 1498-509.
54. Verani RR. Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidaemia. Am J Kidney Dis 1992; 20 (6): 629-34.
55. Bonnet F, Deprele C, Sassolas A et al. Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37 (4): 720-7.
56. Stengel B, Tarver-Carr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479-87.
57. Fox CS, Larson MG, Leip EP et al. Predictors of new onset kidney disease in a community based population. JAMA 2004; 291: 844-50.
58. Solerte SB, Fioravanti M, Schifino N et al. Effects of diet therapy on urinary protein excretion albuminuria and renal hemodynamic function in obese diabetic patients with overt nephropathy. Int J Obes 1989; 13: 203-11.
59. Orth SR, Stockmann A, Conradt C et al. Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998; 54 (3): 926-31.
60. Pinto-Sietsma SJ, Mulder J, Janssen WM et al. Smoking is related to albuminuria and abnormal renal function in non-diabetic persons. Ann Intern Med 2000; 133 (8): 585-91.
61. Perneger TV, Whelton PK, Puddey IB, Klag MJ. Risk of endstage renal disease associated with alcohol consumption. Am J Epidemiol 1999; 150 (12): 1275-81.
62. Klag MJ, Whelton PK, Perneger TV. Analgesics and chronic renal disease. Curr Opin Nephrol Hypertens 1996; 5 (3): 236-41.
63. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and non-steroidal anti-inflammatory drugs. N Engl J Med 1994; 331 (25): 1675-9.
64. Fouque D, Laville M, Boissel JP et al. Controlled low protein diet in chronic renal insufficiency. Meta-analysis. BMJ 1992; 304: 216-20.
65. Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330 (13): 877-84.
66. Zandi-Nejad K, Brenner BM. Strategies to retard the progression of Chronic Kidney Disease. Med Clin N Am 2005; 89: 489-509.
67. Trivedi HS, Pang MM, Campbell A et al. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. AM J Kid Dis 2002; 39: 721-9.
68. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329 (20): 1456-62.
69. Ravid M, Savin H, Jutrin I et al. Long-term stabilising effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118 (8): 577-81.
70. Lebovitz HE, Wiegmann TB, Cnaan A et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S150-5.
71. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20 (10): 1576-81.
72. Nielsen FS, Rossing P, Gall MA et al. Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1997; 46 (7): 1182-8.
73. Estacio RO, Jeffers BW, Hiatt WR et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338 (10): 645-52.
74. Effects of ramipril on cardiovascular and micro-vascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub study. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355 (9200): 253-9.
75. Sano T, Kawamura T, Matsumae H et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17 (5): 420-4.
76. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349 (9069): 1857-63.
77. Wright JT Jr, Bakris G, Greene T et al. SG; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288 (19): 2421-31.
78. Lewis EJ, Hunsicker LG, Clarke WR et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345 (12): 851-60.
79. Brenner BM, Cooper ME, de Zeeuw D et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345 (12): 861-9.
80. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361 (9352): 117-24.
81. Oliver J, Mac Dowell M, Lee YC. Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J Exp Med 1954; 99 (6): 589-604.
82. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339 (20): 1448-56.
83. Ruggenenti P, Perna A, Remuzzi G. GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63 (6): 2254-61.
84. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int Suppl 1994; 45: S145-9.
85. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123 (10): 754-62.
86. Addis T. Glomerular nephritis; diagnosis and treatment. New York. Macmillan; 1947.
87. Levey AS, Greene T, Beck GJ et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10 (11): 2426-39.
88. Pedrini MT, Levey AS, Lau J et al. The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996; 124 (7): 627-32.
89. Kasiske BL, Lakatua JD, Ma JZ, Louis TA. A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 1998; 31 (6): 954-61.
90. Taal MW, Brenner BM. Prevention of progressive renal failure, In: Brady HR, Wilcox CS, editors. Therapy in nephrology and hypertension, companion to Brenner and Rector's The Kidney. Philadelphia; WB Saunders; 2003; p. 641-53.
91. Ravid M, Brosh D, Ravid-Safran D et al. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158 (9): 998-1004.
92. Hunsicker LG, Adler S, Caggiula A et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 1997; 51 (6): 1908-19.
93. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidaemia on the decline in renal function. Hypertension 1995; 26 (4): 670-5.
94. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59 (1): 260-9.
95. Yu HT. Progression of chronic renal failure. Arch Intern Med 2003; 163 (12): 1417-29.
96. Gerstein HC, Mann JF, Pogue J et al. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. Diabetes Care 2000; 23 (Suppl 2): B35-9.
97. Mimran A, Ribstein J, DuCailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diabetes Complications 1994; 8 (3): 150-6.
98. Regalado M, Yang S, Wesson DE. Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension. Am J Kidney Dis 2000; 35 (4): 687-94.
99. Kuriyama S, Tomonari H, Yoshida H et al. Reversal of anaemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77 (2): 176-85.
100. IV. NKF-K/OQI Clinical Practice Guidelines for Anaemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37 (1suppl): S182-238.
101. Cameron JS. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 (Suppl 2): 61-5.
102. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339 (9): 584-90.
103. Praga M, Hernandez E, Andres A et al. Effects of bodyweight loss and captopril treatment on proteinuria associated with obesity. Nephron 1995; 70 (1): 35-41.
104. Curtis BM, Levin A, Parfrey PS. Multiple risk factor intervention in chronic kidney disease: management of cardiac disease in chronic kidney disease patients. Med Clin North Am 2005; 89 (3): 511-23.
105. Levin A, Stevens LA. Executing change in the management of chronic kidney disease: perspectives on guidelines and practice. Med Clin North Am 2005; 89 (3): 701-9.
106. Wald NJ, Law MR. strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326 (7404): 1419.
107. Barsoum RS. Chronic Kidney Disease in the Developing World. N Engl J Med 2006; 354 (10): 997-9.
108. Shyam C, Sreenivas V. Chronic kidney disease: a missing component of integrated control of non-communicable diseases. Indian J Med Res 2005; 122 (5): 451-3.